论文部分内容阅读
目的观察乌司他汀治疗多脏器功能衰竭(MOF)患者的临床疗效。方法抽取2015年6月-2016年6月在医院使用乌司他汀治疗的MOF患者44例,设为研究组,另抽取同期接受常规治疗的MOF患者44例,设为对照组,观察2组患者的生命体征,包括心率(HR)、血氧饱和度(Sp O2)、呼吸频率(RR)和白细胞计数(WBC),使用试剂盒检测白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)水平。结果治疗后研究组患者的HR及RR均低于对照组,Sp O2高于对照组,WBC低于对照组,差异有统计学意义(P<0.05)。研究组患者治疗后IL-6和TNF-α水平低于对照组,差异有统计学意义(P<0.05)。结论 MOF患者使用乌司他汀能使患者的临床症状好转,取得较好的治疗效果,适合推广应用。
Objective To observe the clinical efficacy of ulinastatin in patients with multiple organ failure (MOF). Methods Forty-four patients with MOF who were treated with ulinastatin in the hospital from June 2015 to June 2016 were enrolled in this study. Forty-four patients with MOF were enrolled as the control group and two groups of patients (HR), Sp O2, respiratory rate (RR) and white blood cell count (WBC) were detected by ELISA kit. IL-6 and TNF- TNF-α) levels. Results After treatment, HR and RR of study group were lower than that of control group, Sp O2 was higher than that of control group, WBC was lower than that of control group, the difference was statistically significant (P <0.05). The levels of IL-6 and TNF-α in the study group were lower than those in the control group (P <0.05). Conclusion The use of ulinastatin in patients with MOF can improve the clinical symptoms of patients and achieve better therapeutic effect, which is suitable for popularization and application.